阿帕替尼联合替吉奥治疗晚期食管癌的有效性和安全性分析  

Efficacy and Safety of Apatinib combined with Tigio in the Treatment of Advanced Esophageal Cancer

作　　者：陈金虹 张燕[1] 鲁小敏[1] CHEN Jinhong;ZHANG Yan;LU Xiaomin(Haian People's Hospital Affiliated to Nantong University,Haian,226600)

机构地区：[1]南通大学附属海安人民医院,226600

出　　处：《实用癌症杂志》2020年第9期1475-1477,共3页The Practical Journal of Cancer

基　　金：江苏省卫生健康委员会项目(编号:H400513)。

摘　　要：目的探讨阿帕替尼联合替吉奥治疗晚期食管癌的有效性和安全性。方法将食管癌患者86例分为对照组和观察组,对照组予以阿帕替尼治疗,观察组在对照组的基础上予以替吉奥治疗,治疗4周后评估两组的临床疗效、不良反应、KPS评分生活质量。结果治疗4周后,对照组ORR为4.7%,DCR为76.7%。观察组ORR为18.6%,DCR为93.0%。观察组的ORR,DCR均明显高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生情况比较,包括蛋白尿,食管炎,白细胞下降,贫血,高血压,消化道反应,出血,肝功能损伤,差异无统计学意义(P>0.05)。对照组患者持续治疗4周后生活质量满意29例;观察组持续治疗4周后生活质量满意40例,两组生活质量满意例数比较(χ2=0.887,P=0.003),差异具有统计学意义,观察组优于对照组。结论阿帕替尼联合替吉奥治疗晚期食管癌临床效果显著,安全性高,值得临床推广应用。Objective To investigate the efficacy and safety of apatinib combined with tigio in the treatment of advanced esophageal cancer.Methods 86 patients with esophageal cancer were selected.According to the treatment plan,the control group was treated with apatinib,and the observation group was treated with tigio on the basis of the control group.The clinical efficacy,adverse reactions and quality of life of the 2 groups were evaluated after 4 weeks of treatment.Results After 4 weeks of treatment,the ORR and ORR of the control group were 4.7%and 76.7%respectively.The ORR and DCR of the observation group were18.6%and 93.0%,respectively.The ORR,DCR of the observation group was significantly higher than that of the control group(P<0.05).There was no significant difference in the occurrence of adverse reactions between the 2 groups,including albuminuria,esophagitis,leukopenia,anemia,hypertension,digestive tract reaction,bleeding and liver function injury(P>0.05).29 patients in the control group were satisfied with the quality of life after 4 weeks of continuous treatment,40 patients in the observation group were satisfied with the quality of life after 4 weeks of continuous treatment,and the number of satisfactory cases of quality of life in the 2 groups(χ2=0.887,P≤0.003)was statistically significant,and the observation group was superior to the control group.Conclusion Apatinib combined with tigio is effective and safe in the treatment of advanced esophageal cancer.

关 键 词：阿帕替尼 替吉奥治 晚期食管癌 有效性 安全性 

分 类 号：R735.1[医药卫生—肿瘤]